Official Journal of Research Center for Gastroenterology and Liver Diseases
Authors
Detectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people who have been exposed to hepatitis C virus (HCV) and remain anti-HCV negative are of interest for HCV vaccine development; however, limited research addresses this area.
In a cohort of HCV antibody and RNA negative PWID, we assessed whether the presence of HCV-specific IFN-? responses or genetic associations provide any evidence of protection from HCV infection.
One hundred and ninety-eight participants were examined longitudinally for clinical, behavioral, social, environmental and genetic characteristics (IFNL3 genotype [formally IL-28B] and HLA type). Sixty-one of the 198 participants were HCV antibody and RNA negative, with 53 able to be examined longitudinally for HCV-specific IFN-? ELISpot T cell responses.
Ten of the 53 HCV antibody and RNA negative participants had detectable HCV-specific IFN-? responses at baseline (18%). The magnitude of IFN-? responses averaged 131 +/- 96 SFC/106 PBMC and the breadth was mean 1 +/- 1 pool positive. The specificity of responses were mainly directed to E2, NS4b and NS5b. Participants with (10) and without (43) HCV-specific IFN-? responses did not differ in behavioral, clinical or genetic characteristics (P > 0.05). There was a larger proportion sharing needles (with 70%, without 49%, P = 0.320) and a higher incidence of HCV (with 35.1 per 100 py, 95% CI 14.6, 84.4, without 16.0 per 100 py, 95% CI 7.2, 35.6, P = 0.212) in those with IFN-? responses, although not statistically significant. Half the participants with baseline IFN-? responses became HCV RNA positive (5/10), with one of these participants spontaneously clearing HCV. The spontaneous clearer had high magnitude and broad Th1 responses, favorable IFNL3 genotype and favorable HLA types.
This study demonstrated the detection of HCV-specific IFN-? responses in HCV antibody and RNA negative individuals, with a tendency for HCV-specific IFN-? responses to be associated with HCV exposure. The potential role of HCV-specific IFN-? responses in those who remained HCV RNA negative is of value for the development of novel HCV therapeutics.
© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
wangjian W, Pingping W, Guiju X, wangjian W, Pingping W, et al. Antibody against Interferon-α 2b in Serum of the Patients with Chronic Hepatitis C and its Clinical Significance: A Clinical Trial. Hepat Mon. 2009;9(2):e92963. doi:
Miri SM, Sharafi H, Pouryasin A, Behnava B, Keshvari M, et al. The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy. Hepat Mon. 2017;17(4):e12301. doi: https://doi.org/10.5812/hepatmon.46539
Kurelac I, papic N, Sakoman S, orban M, Dusek D, et al. Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon. 2011;11(12):. doi: https://doi.org/10.5812/kowsar.1735143X.779
Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014;14(10):e22649. doi: https://doi.org/10.5812/hepatmon.22649
Sharhani A, Mehrabi Y, Noroozi A, Nasirian M, Higgs P, et al. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran. Hepat Mon. 2017;17(10):e58739. doi: https://doi.org/10.5812/hepatmon.58739
More by these authors
Last Update: 15 hours ago
Last Update: 15 hours ago
Last Update: 12 years ago
Last Update: 3 days ago